Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study

Phase I Study ◽

Growth Factor Receptor ◽

Japanese Patients ◽

Solid Tumours ◽

Fibroblast Growth ◽

First‐in‐human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors

Cancer Science ◽

10.1111/cas.14265 ◽

2020 ◽

Vol 111 (2) ◽

pp. 571-579 ◽

Cited By ~ 1

Author(s):

Takafumi Koyama ◽

Toshio Shimizu ◽

Satoru Iwasa ◽

Yutaka Fujiwara ◽

Shunsuke Kondo ◽

...

Keyword(s):

Growth Factor ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Growth Factor Receptor ◽

Advanced Solid Tumors ◽

Fibroblast Growth ◽

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-18-3334 ◽

2019 ◽

Vol 25 (16) ◽

pp. 4888-4897 ◽

Cited By ~ 37

Author(s):

Rastislav Bahleda ◽

Antoine Italiano ◽

Cinta Hierro ◽

Alain Mita ◽

Andres Cervantes ◽

...

Keyword(s):

Growth Factor ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Growth Factor Receptor ◽

Fibroblast Growth ◽

Multicenter Phase ◽

Abstract 3738: Use of tumor mRNA expression for patient selection in a phase I study of the pan-fibroblast growth factor receptor inhibitor BAY 1163877

10.1158/1538-7445.am2017-3738 ◽

2017 ◽

Cited By ~ 1

Author(s):

Peter Ellinghaus ◽

Matthias Ocker ◽

Sebastian Bender ◽

Christoph Kneip ◽

Stuart Ince ◽

...

Keyword(s):

Growth Factor ◽

Phase I ◽

Patient Selection ◽

Phase I Study ◽

Growth Factor Receptor ◽

Fibroblast Growth ◽

Tumor Mrna ◽

First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody–Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer

Targeted Oncology ◽

10.1007/s11523-019-00670-4 ◽

2019 ◽

Vol 14 (5) ◽

pp. 591-601 ◽

Cited By ~ 7

Author(s):

Sung-Bae Kim ◽

Funda Meric-Bernstam ◽

Aparna Kalyan ◽

Aleksei Babich ◽

Rong Liu ◽

...

Keyword(s):

Growth Factor ◽

Phase I ◽

Advanced Cancer ◽

Phase I Study ◽

Growth Factor Receptor ◽

Fibroblast Growth ◽

Antibody Drug Conjugate ◽

Antibody Drug

Abstract CT094: Phase I study of fibroblast growth factor receptor 2 antibody-drug conjugate (FGFR2-ADC) BAY 1187982 in patients with advanced cancer

10.1158/1538-7445.am2017-ct094 ◽

2017 ◽

Author(s):

Sung-Bae Kim ◽

Funda Meric-Bernstam ◽

Jordan Berlin ◽

Sabine Wittemer-Rump ◽

Motonobu Osada ◽

...

Keyword(s):

Growth Factor ◽

Phase I ◽

Advanced Cancer ◽

Phase I Study ◽

Growth Factor Receptor ◽

Fibroblast Growth ◽

Antibody Drug Conjugate ◽

Antibody Drug

Abstract LB-145: Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors .

10.1158/1538-7445.am2013-lb-145 ◽

2013 ◽

Cited By ~ 23

Author(s):

Fabrice Andre ◽

Malcolm Ranson ◽

Emma Dean ◽

Andrea Varga ◽

Ruud van der Noll ◽

...

Keyword(s):

Growth Factor ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Growth Factor Receptor ◽

Advanced Solid Tumors ◽

Fibroblast Growth

Abstract CT215: A phase I trial of LY2874455, a fibroblast growth factor receptor inhibitor, in patients with advanced cance

10.1158/1538-7445.am2014-ct215 ◽

2014 ◽

Cited By ~ 6

Author(s):

Jeanne Tie ◽

Yung-Jue Bang ◽

Young Suk Park ◽

Yoon-Koo Kang ◽

David Monteith ◽

...

Keyword(s):

Growth Factor ◽

Phase I ◽

Phase I Trial ◽

Growth Factor Receptor ◽

Fibroblast Growth ◽

Exploratory biomarker analysis of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.11010 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 11010-11010 ◽

Cited By ~ 9

Author(s):

Elaine Kilgour ◽

David Ferry ◽

Matilde Saggese ◽

Hendrik-Tobias Arkenau ◽

Claire Rooney ◽

...

Keyword(s):

Growth Factor ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Growth Factor Receptor ◽

Advanced Solid Tumors ◽

Fibroblast Growth ◽

Biomarker Analysis

Abstract A099: Safety, tolerability, pharmacokinetics, and efficacy of pan-fibroblast growth factor receptor inhibitor rogaratinib in Japanese patients with refractory, locally advanced metastatic solid tumors selected with a novel, mRNA-based patient selection strategy

10.1158/1535-7163.targ-17-a099 ◽

2018 ◽

Author(s):

Makoto Tahara ◽

Shunji Takahashi ◽

Matthias Ocker ◽

Stuart Ince ◽

Hendrik Nogai ◽

...

Keyword(s):

Growth Factor ◽

Patient Selection ◽

Locally Advanced ◽

Growth Factor Receptor ◽

Japanese Patients ◽

Selection Strategy ◽

Fibroblast Growth ◽

developmental therapeutics Phase I study of the pan-fibroblast growth factor receptor (FGFR) inhibitor BAY 1163877 with expansion cohorts for subjects based on tumor FGFR mRNA expression levels

Annals of Oncology ◽

10.1093/annonc/mdw435.10 ◽

2016 ◽

Vol 27 ◽

pp. vi558 ◽

Cited By ~ 4

Author(s):

M. Joerger ◽

R. Soo ◽

B.C. Cho ◽

A. Navarro Mendivil ◽

C. Sayehli ◽

...

Keyword(s):

Growth Factor ◽

Phase I ◽

Mrna Expression ◽

Phase I Study ◽

Growth Factor Receptor ◽

Fibroblast Growth ◽

Developmental Therapeutics ◽

Mrna Expression Levels